BR112015009107A2 - agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo - Google Patents

agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR112015009107A2
BR112015009107A2 BR112015009107A BR112015009107A BR112015009107A2 BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2 BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A BR112015009107 A BR 112015009107A BR 112015009107 A2 BR112015009107 A2 BR 112015009107A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
acceptable salt
growth hormone
receptor agonist
hormone secretagogue
Prior art date
Application number
BR112015009107A
Other languages
English (en)
Portuguese (pt)
Inventor
Furuya Mayumi
Murayama Norihito
Matsuo Tsuyoshi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112015009107A2 publication Critical patent/BR112015009107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
BR112015009107A 2012-10-24 2013-10-23 agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo BR112015009107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Publications (1)

Publication Number Publication Date
BR112015009107A2 true BR112015009107A2 (pt) 2017-11-14

Family

ID=50544716

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015009107A BR112015009107A2 (pt) 2012-10-24 2013-10-23 agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo

Country Status (11)

Country Link
US (1) US20150265680A1 (https=)
EP (1) EP2913063B1 (https=)
JP (1) JP6262661B2 (https=)
KR (3) KR20200108494A (https=)
CN (2) CN104853778A (https=)
AU (1) AU2013335678B9 (https=)
BR (1) BR112015009107A2 (https=)
CA (1) CA2889499C (https=)
IN (1) IN2015DN04172A (https=)
RU (1) RU2655811C2 (https=)
WO (1) WO2014065341A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106636A (zh) 2014-11-12 2017-08-29 利瑞克药品有限公司 肠内喂养不耐受的治疗
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
US12429487B2 (en) 2018-12-06 2025-09-30 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CA2340701C (en) 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers
ES2401939T3 (es) 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CA2395996A1 (en) 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
ATE370119T1 (de) 2000-06-13 2007-09-15 Zentaris Gmbh Wachstumhormonsekretionsförderer
CN100491395C (zh) 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
CA2625341A1 (en) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用

Also Published As

Publication number Publication date
WO2014065341A1 (ja) 2014-05-01
CA2889499C (en) 2019-09-10
RU2015119472A (ru) 2016-12-20
AU2013335678A1 (en) 2015-05-21
EP2913063A1 (en) 2015-09-02
KR102499918B1 (ko) 2023-02-14
CN110354265A (zh) 2019-10-22
KR20150070180A (ko) 2015-06-24
AU2013335678B9 (en) 2024-12-12
AU2013335678B2 (en) 2017-10-26
KR20220051418A (ko) 2022-04-26
RU2655811C2 (ru) 2018-05-29
CA2889499A1 (en) 2014-05-01
JP6262661B2 (ja) 2018-01-17
US20150265680A1 (en) 2015-09-24
KR20200108494A (ko) 2020-09-18
JPWO2014065341A1 (ja) 2016-09-08
CN104853778A (zh) 2015-08-19
IN2015DN04172A (https=) 2015-10-16
EP2913063B1 (en) 2019-09-11
EP2913063A4 (en) 2016-07-20
HK1214152A1 (en) 2016-07-22

Similar Documents

Publication Publication Date Title
BR112015010314A2 (pt) composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios
CL2014000802A1 (es) Proceso para la preparacion de estetrol, util para terapia de reemplazo hormonal y la anticoncepcion.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
IL233324A (en) Dimeric compounds as agonist receptor for fgf, process for their preparation and medical use
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
EP2991711A4 (en) DRUGS CHARGE DEVICE
BR112013017752A8 (pt) uso de um antagonista do vegf e formulação farmacêutica
IL233592B (en) The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain
IL241012A0 (en) Use of formyl peptide receptor 2 agonists for the treatment of ocular inflammatory diseases
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
PL3409270T3 (pl) Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta- adrenergiczny do podawania wziewnego
BR112013016862A2 (pt) combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson
SG11201602477YA (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
BR112013010102A2 (pt) microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
ZA201309683B (en) Neutraling prolactin receptor antibody mat3 and its therapeutic use
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
GB201312344D0 (en) Liposomal drug delivery system for bone cements
HRP20191361T1 (hr) Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe
EP2990040A4 (en) Therapeutic agent for eyeground disease
BR112015012443A2 (pt) composição de limpeza, método de limpeza do corpo humano, uso da composição e método para prover limpeza
EP3019130A4 (en) DRUG-PROLONGED TRANSDERMAL RELEASE KIT USING LIQUID OR SEMI-SOLID COMPOSITIONS AND METHOD OF USING THE SAME
EP2981258A4 (en) PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMID
IL227705A0 (en) Topical antifungal agent, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.